Midazolam
| Evidence Level: L3 | Predicted Indications: 1 |
Table of Contents
Midazolam: From Its Registered Indication to Insomnia
One-Sentence Summary
Midazolam is a short-acting benzodiazepine that is marketed in South Africa as an injection (Dormicum). The registration record supplied does not state its approved indication. The TxGNN model predicts it may be effective for insomnia. Support is mainly older midazolam sleep studies from the 1980s and 1990s, with 2 midazolam-related trials that measure sleep or target sleep disturbance and no modern trial testing midazolam as an insomnia treatment.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L3 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this record. Midazolam belongs to the benzodiazepine class. These drugs enhance GABA-A receptor signalling, which produces sedative and hypnotic effects. That is mechanistically consistent with treating insomnia.
The high TxGNN score is plausible, but it probably reflects the shared GABAergic drug class rather than midazolam-specific evidence. Oral midazolam has also been used as a hypnotic in some countries. This may therefore be a question of labelling or regional approval rather than true repurposing. The original indication is not stated in the registration data supplied, so this needs confirming against the SAHPRA-approved Professional Information (PI).
Clinical Trial Evidence
No trial tests midazolam as a treatment for chronic insomnia. The trials below are the closest matches. The remaining registered trials retrieved for this prediction (mostly dexmedetomidine, acupuncture, behavioural or device studies) are not relevant to midazolam for insomnia.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06407518 | NA | Recruiting | 280 | Preoperative oral midazolam vs placebo in colorectal cancer patients with sleep disturbance or anxiety. The outcome is postoperative pain, not sleep. |
| NCT02142595 | Phase 4 | Completed | 111 | Postoperative sleep quality after dexmedetomidine or midazolam sedation during prostate resection. Midazolam is a sedation comparator, not an insomnia treatment. |
| NCT01966315 | N/A | Terminated | 5 | Dexmedetomidine vs midazolam on polysomnography-measured sleep in ventilated ICU patients. Too small to interpret. |
| NCT00826553 | Phase 1 | Terminated | 6 | Polysomnography in ventilated patients sedated with α2 agonists vs GABA agonists. Too small to interpret. |
No SANCTR or PACTR registrations were found in the data.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6138072 | 1983 | Double-blind controlled study | Br J Clin Pharmacol | Midazolam 15 mg vs Vesparax in 30 women with insomnia secondary to neuromuscular disease. Both were effective hypnotics. Midazolam was better tolerated and did not cause the hangover seen with Vesparax. |
| 2121802 | 1990 | Randomised double-blind study | J Clin Psychopharmacol | Multicentre, parallel-group design comparing flurazepam and midazolam over 14 days in chronic insomniacs, looking at sleep, performance and mood. |
| 2229461 | 1990 | Multicentre study (executive summary) | J Clin Psychopharmacol | Executive summary of the same 14-day flurazepam vs midazolam study in chronic insomniacs. No abstract available. |
| 6120704 | 1981 | Dose-finding pilot study | Arzneimittel-Forschung | Oral midazolam 10–30 mg in 75 hospitalised patients with mild to moderate insomnia. The study aimed to establish the optimal dose range. |
| 2883820 | 1986 | Review | Acta Psychiatr Scand Suppl | Review of hypnotic use. It notes that benzodiazepines with different pharmacokinetic profiles are all clinically effective. |
These studies are 35 to 45 years old and used older methods. They support plausibility rather than current-standard efficacy.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| T/2.2/207 | Dormicum | Injection | Not stated in the record supplied |
The only registered form in the data is an injection, and no oral formulation appears. Insomnia treatment normally relies on an oral hypnotic, so route compatibility is unresolved. Essential Medicines List status is not available in the record.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible and there are older midazolam insomnia studies, but the evidence is L3. There is no modern trial of midazolam for insomnia, and the only registered South African form is an injection. Safety data cannot yet be reviewed because the PI warnings and contraindications are missing, which blocks the safety screening step.
To proceed, the following is needed:
- SAHPRA PI warnings and contraindications (blocking gap)
- The approved indication text for Dormicum, to confirm whether insomnia is a repurposing question or a labelling question
- Confirmation of whether any oral midazolam product is registered in South Africa
- Mechanism of action data from DrugBank
- A review of the older insomnia studies for current relevance, or newer insomnia-specific trial data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.